orlistat prescription criteria gabapentin 300 mg side effects uk levaquin 500 mg xenical prescription cost gabapentin 600 mg overdose cialis generico barato cialis 20mg prix cialis en andorre cuanto vale la viagra acheter levitra en ligne generic proscar (5mg finasteride) bupropion sr 150mg tablets (12 h) side effects clomid tablets for sale south africa finasteride 5mg tablets side effects albendazole usp manufacturer viagra remboursé par la sécu acheter tadalafil france acheter viagra sur net comprar cialis en españa tadalafil 40 mg spain azithromycin tablets price in india diflucan ordering online amoxicillin side effects birth control pills fluconazole tablet price in india
medicament venlafaxine mylan priligy vente en ligne medicament azithromycin 250 mg

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

Mon, Jun 20, 2011

Oral Cancer News

Source: The Lancet



Australia introduced a human papillomavirus (HPV) vaccination programme with the quadrivalent HPV vaccine for all women aged 12—26 years between 2007 and 2009. We analysed trends in cervical abnormalities in women in Victoria, Australia, before and after introduction of the vaccination program.


With data from the Victorian Cervical Cytology Registry between 2003 and 2009, we compared the incidence of histopathologically defined high-grade cervical abnormalities (HGAs, lesions coded as cervical intraepithelial neoplasia of grade 2 or worse or adenocarcinoma in situ; primary outcome) and low-grade cytological abnormalities (LGAs) in five age groups before (Jan 1, 2003, to March 31, 2007) and after (April 1, 2007, to Dec 31, 2009) the vaccination programme began. Binary comparisons between the two periods were done with Fisher’s exact test. Poisson piecewise regression analysis was used to compare incident rate trends.


After the introduction of the vaccination programme, we recorded a decrease in the incidence of HGAs by 0·38% (95% CI 0·61—0·16) in girls younger than 18 years. This decrease was progressive and significantly different to the linear trend in incidence before introduction of the vaccination (incident rate ratio 1·14, 1·00—1·30, p=0·05). No similar temporal decline was recorded for LGAs or in older age groups.


This is the first report of a decrease in incidence of HGAs within 3 years after the implementation of a population-wide HPV vaccination programme. Linkage between vaccination and screening registers is needed to confirm that this ecological observation is attributable to vaccination and to monitor participation in screening among vaccinated women.



Print Friendly
Be Sociable, Share!
, , , ,

Leave a Reply

You must be logged in to post a comment.